Investors

Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

35+
Approved products
15
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration

Financial metrics

$2.8bn
Portfolio Receipts
(2024)
$2.6bn
Adjusted EBITDA
(2024)
$2.4bn
Average annual capital deployed (2019-2024)
$2.8bn
Announced value of transactions (2024)

Corporate presentation

SEC filings

Filing Date Form View
Loading…
All Filings

Latest releases

Royalty Pharma Announces R&D Funding Collaboration with Biogen

NEW YORK, NY, February 12, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).  

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe